Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Alirocumab (Praluent) vs Ezetimibe (Zetia): Ezetimibe (Zetia) has the stronger overall evidence (4.4 vs 4.5/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Ezetimibe (Zetia) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Alirocumab (Praluent) and Ezetimibe (Zetia) have evidence — compare verdict strength side-by-side.
Prescription dosing is 75 mg or 150 mg subcutaneously every 2 weeks (a 300 mg every-4-weeks option exists), titrated by a clinician to the LDL-C target. A prescription drug; not a self-administered supplement regimen.
any
Subcutaneous prefilled pen/syringe (alirocumab)
10 mg once daily, with or without food, alone or added to a statin — under a clinician. A prescription drug; not a self-directed supplement regimen.
any
Oral tablet (ezetimibe 10 mg)
Within weeks
Months to years
Years
At each injection
2–4 weeks
Months to years
Throughout use
Throughout use
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
The New England journal of medicine (2018) · Rct · n=18924
ODYSSEY OUTCOMES randomized trial of ~18,900 patients 1–12 months after acute coronary syndrome on intensive statins
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
The New England journal of medicine (2015) · Rct · n=2341
ODYSSEY LONG TERM randomized trial in high-cardiovascular-risk patients on maximally tolerated statins
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.
European heart journal (2015) · Rct · n=735
Pooled ODYSSEY FH I and FH II randomized trials in 735 heterozygous familial-hypercholesterolemia patients
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
The New England journal of medicine (2015) · Rct · n=18144
IMPROVE-IT randomized trial: ~18,000 patients stabilized after acute coronary syndromes
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Lancet (London, England) (2011) · Rct · n=9438
SHARP randomized placebo-controlled trial in chronic kidney disease (n≈9,400)
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
The New England journal of medicine (2008) · Rct · n=1873
SEAS randomized trial in patients with mild-to-moderate aortic stenosis
Ezetimibe (Zetia) has a higher evidence score (4.4/10 vs 4.5/10) and wins in 2 of 3 categories.
For support heart health, Alirocumab (Praluent) has a higher relevance score (80 vs 68).
No known interactions between Alirocumab (Praluent) and Ezetimibe (Zetia) have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.